+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biodefense Market, By Product, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

  • PDF Icon

    Report

  • 167 Pages
  • July 2021
  • Region: Global
  • Coherent Market Insights Pvt Ltd.
  • ID: 5398271
Biodefense is a military or emergency response term that is frequently discussed in the context of bio-war or bioterrorism. Biodefense also refers to actions taken to restore biosecurity to a group of organisms that are or may be vulnerable to biological threats or infectious diseases. A biological attack, also known as bioterrorism, is the deliberate release of viruses, bacteria, or other germs capable of sickening or killing people, livestock, or crops. The bacteria that causes anthrax, Bacillus anthracis, is considered as one of the most likely agents to be used in a biological attack.



Market Dynamics


Market players and some global foundations are focused on developing vaccines against Nipah Virus, this could contribute to the growth of the global biodefense market over the forecast period. For instance on March 13, 2020, the Coalition for Epidemic Preparedness Innovations (CEPI), a global foundation that takes donations from philanthropic organizations, funded the first Nipah virus vaccine candidate to enter Phase 1 clinical trials. The Phase 1 trial is a randomized, placebo-controlled dose-finding study to assess the safety, tolerability, and immunogenicity of the HeV-sG-V Nipah vaccine candidate. The study is being conducted at Cincinnati Children's Hospital Medical Center in Cincinnati, U.S., and is sponsored by Auro Vaccines LLC, a wholly owned indirect subsidiary of Aurobindo Pharma Ltd., and led by Program for Appropriate Technology in Health (PATH), a global non-profit organization.

Market players are focusing on product launches, which is expected to strengthen their position in the global biodefense market. For instance, on July 01, 2020, Johnson & Johnson, world’s largest healthcare company announced that the European Commission (EC) approved its subsidiary Janssen Pharmaceutical Companies' Ebola vaccine regimen for the prevention of Ebola Virus Disease.

Market players are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, this is expected to drive the growth of the global biodefense market. For instance, on February 26, 2020, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, partnered with Southern Research, a non-profit scientific research organization, to develop a potential COVID-19 vaccine based on Tonix's proprietary horsepox vaccine platform (TNX-1800).

Key features of the study:

  • This report provides an in-depth analysis of global biodefense market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global biodefense market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Emergent Biosolutions Inc., SIGA Technologies Inc., Bavarian Nordic A/S, Elusys Therapeutics Inc., Ichor Medical Systems Inc., Amgen Inc., Cleveland BioLabs Inc., Dynavax Technologies Corporation, Alnylam Pharmaceuticals Inc., and XOMA Corporation.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global biodefense market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global biodefense market.

Detailed Segmentation


Global Biodefense Market, By Product


  • Anthrax
  • Small Pox
  • Botulism
  • Radiation
  • Others

Global Biodefense Market, By End User


  • Hospitals
  • Ambulatory Care Centers
  • Research Organizations
  • Military
  • Others

Company Profiles


  • Emergent Biosolutions Inc.*
  • SIGA Technologies Inc.
  • Bavarian Nordic A/S
  • Elusys Therapeutics Inc.
  • Ichor Medical Systems Inc.
  • Amgen Inc.
  • Cleveland BioLabs Inc.
  • Dynavax Technologies Corporation
  • Alnylam Pharmaceuticals Inc.
  • XOMA Corporation.

“*” marked represents similar segmentation in other categories in the respective section.
Frequently Asked Questions about the Biodefense Market

What is the estimated value of the Biodefense Market?

The Biodefense Market was estimated to be valued at $12.2 Billion in 2021.

What is the growth rate of the Biodefense Market?

The growth rate of the Biodefense Market is 4.8%, with an estimated value of $17 Billion by 2028.

What is the forecasted size of the Biodefense Market?

The Biodefense Market is estimated to be worth $17 Billion by 2028.

Who are the key companies in the Biodefense Market?

Key companies in the Biodefense Market include Emergent Biosolutions Inc., SIGA Technologies Inc., Bavarian Nordic A/S, Elusys Therapeutics Inc., Ichor Medical Systems Inc., Amgen Inc., Cleveland BioLabs Inc., Dynavax Technologies Corporation and XOMA Corporation..

Table of Contents

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Product
  • Market Snippet, By End User
  • Market Snippet, By Region

3. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Porter’s Analysis
  • Industry Trends
  • Key Highlights
  • Epidemiology
  • Reimbursement Scenario
  • Regulatory Scenario
  • Product Launch and Approvals
  • Acquisition and Collaboration Scenario

4. COVID – 19 Impact Analysis
  • COVID-19 Epidemiology
  • Impact of COVID-19 on Demand and Supply of Biodefense products
  • Impact of COVID-19 on the overall Healthcare Sector

5. Global Biodefense Market, By Product, 2017-2028 (US$ Billion)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
  • Anthrax
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Small Pox
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Botulism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Radiation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

6. Global Biodefense Market, By End User, 2017 - 2028 (US$ Billion)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
  • Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Ambulatory Care Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Research Organizations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Military
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

7. Global Biodefense Market, By Region, 2017 - 2028 (US$ Billion)
  • Introduction
  • Market Share Analysis, By Region, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
  • Regional Trends
  • North America
  • Market Size and Forecast, By Product, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By End User, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
  • U.S.
  • Canada
  • Latin America
  • Market Size and Forecast, By Product, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By End User, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Market Size and Forecast, By Product, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By End User, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Market Size and Forecast, By Product, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By End User, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Market Size and Forecast, By Product, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By End User, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Market Size and Forecast, By Product, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By End User, 2017 - 2028 (US$ Bn)
  • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Bn)
  • South Africa
  • Central Africa
  • North Africa

8. Competitive Landscape
  • Company Profiles
  • Emergent Biosolutions Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • SIGA Technologies Inc.
  • Bavarian Nordic A/S
  • Elusys Therapeutics Inc.
  • Ichor Medical Systems Inc.
  • Amgen Inc.
  • Cleveland BiolLabs Inc.
  • Dynavax Technologies Corporation
  • Alnylam Pharmaceuticals Inc.
  • XOMA Corporation
  • Analyst Views

9. Section
  • Research Methodology
  • About us
  • Contact

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Emergent Biosolutions Inc.
  • SIGA Technologies Inc.
  • Bavarian Nordic A/S
  • Elusys Therapeutics Inc.
  • Ichor Medical Systems Inc.
  • Amgen Inc.
  • Cleveland BioLabs Inc.
  • Dynavax Technologies Corporation
  • Alnylam Pharmaceuticals Inc.
  • XOMA Corporation.